reason report
result total oper loss ep
higher revenu lighter spend anticip
consensu royalti incom trelegi profit share
op yupelri continu build offer long-term
valuat support stock compani proprietari
program continu advanc proof concept
pivot ampreloxetin trial royalti incom
gsk sale trelegi mm quarterli global
sale compani stock pressur quarter base
royalti disput appar forc sell least
one major sharehold despit royalti disput compani
posit secur expect share trelegi royalti
next coupl month end compani also confirm
intent servic non-recours debt interest
capit contribut cash yupelri least
arbitr final model updat account lower
expens price target increas
reiter outperform rate therav
net debt total capit
dcf use dr tgr
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep quarterli ep may total annual sum due chang share outstand
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform therav biotechnolog compani form via
spin-out thrx divers set asset robust engin
previous produc sever fda approv drug includ anoro breo vibativ
leverag deep expertis drug deliveri compani late earli stage pipelin
product oper via proven mechanisms-of-act aim differenti either
beneficial/us mode administr revefenacin better safeti /- wider therapeut
window tbph yupelri nebul formul long act
muscarin antagonist lama w/ partner op launch strongli late
approv therav receiv signific share profit product break
even passiv recipi stand earn net royalti
sale gsk close tripl trelegi recent approv us
europ prior medacorp survey work suggest success close tripl could becom
stapl copd standard-of-car model suggest tripl could becom blockbust
opportun temper slower-than-expect launch breo/anoro still
forecast ww tripl sale peak beyond tbph commercial/partn asset
compani also develop improv jak inhibitor jaki partner op
inflammatori bowel diseas ibd norepinephrin serotonin reuptak inhibitor nsri
neurogen orthostat hypotens noh drug leverag novel
deliveri uniqu compound proven mechanisms-of-act could offer superior
safeti and/or treatment effect wider therapeut window
therav report revenu higher estim
higher consensu stronger-than-expect revenu mainli due up-front payment
expand licens right nebul revefenacin china
adjac geographi collabor revenu primarili
continu account recognit prior period up-front collabor payment yupelri
launch continu ramp compani yet achiev posit cash flow
product total expens quarter consensu estim
lighter-than-expect expens mainli due lower employee-rel cost
lower sg associ elimin therav share sell
expens vibativ compani report ep compar consensu
estim
global trelegi net sale qoq therav earn royalti
incom qoq despit strong growth trelegi impli royalti incom
compani receiv royalti payment past two quarter disput
withhold someth concern given therav recent non-
recours debt rais securit therav royalti incom trelegi therav
must remit portion royalti pay interest debt debt agreement allow
therav make capit contribut cover shortfal period
therefor therav pressur resolv legal issu order
stay compliant debt term els payment shortfal ad princip
amount least octob per debt agreement
disput arbitr compani expect resolut
arbitr occur year perceiv risk import compon valu could
act overhang therav stock even newli commerci respiratori asset
continu strong sale momentum seen partnership develop incept
understand natur agreement respect royalti remain confid
therav ultim prevail disput secur cash consist
partnership term expect compani stock react posit overhang
resolv potenti next month
pipelin product progress track multipl late stage trial readout
expect
therav continu enrol patient ulcer coliti uc crohn diseas cd
phase ii/ trial neurogen orthostat hypotens noh phase trial
ampreloxetin none trial report data second half howev
therav report proof concept poc data investig dri powder inhal pan-
jaki septemb year studi aim enrol particip accord
clinicaltri gov design evalu safeti provid biomark data healthi
volunt asthmat patient elev nitric oxid level treat day
multipl dose addit regulatori applic trelegi asthma plan
second half year base posit data phase captain studi
believ lack signific exacerb benefit label may caus challeng payer
reimburs access therav suggest full data address potenti
improv sever exacerb time first exacerb could import
data payer negoti
solid launch yupelri underway expand global collabor
base expand collabor agreement receiv exclus develop
commerci right china adjac territori return therav receiv
up-front payment therav elig receiv
futur mileston new agreement unlik us agreement profit share
assum respons aspect develop commerci pay
therav tier royalti net sale expect therav benefit larg copd
market china secur approv year although signific discount access
hurdl expect
yupelri us launch trend posit drug current formulari vs
cover account total therav disclos patient
prescrib yupelri date continu repres impress start
strong us launch continu potenti ex-u royalti come china launch
expect yupelri gener posit cash flow compani sometim
model updat account yupelri china deal grow trelegi royalti lower expens
pt follow updat financi result quarter manag disclosur
commentari updat revenu expens earn forecast
therav increas revenu forecast slightli account latest mileston
payment grow cash stream trelegi lower expens
forecast consist compani latest commentari guidanc quarterli result
ep estim forecast reduc loss slightli greater loss
continu forecast break-even beyond price target increas
reiter outperform rate therav stock
estim price target month use dcf analysi discount
rate termin growth rate discount rate consist model
biotech de-risk ph asset multipl program develop
higher risk aldr valuat inclus net cash
investor face multipl risk includ limit
commerci risk gsk trelegi close tripl combin
signific clinic risk earli stage program given stage develop
partnership risk maxim opportun inflammatori
develop risk sinc exploratori phase ii data enter
dilut risk compani need equiti rais opt-in
believ could impact stock significantli
loss oper
loss incom tax
provis incom tax
share count period basic dilut
guidanc
svb leerink llc research compani file zack factset consensu
svb leerink llc research compani file zack factset consensu
pipelin program includ current model
pipelin program exclud current
non-ibd indic jak inhibitor
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
approv china expect
arbitr hear commenc
resolut expect
svb leerink llc research compani file
equival
chang
chg work cap
share outstand includ option warrant
